MSF launches global action against GSK and Pfizer over pneumonia vaccine price
November 12, 2015Manufacturing and Production, Sales and Marketing Doctors Without Borders, GSK, MSF, Médecins Sans Frontières, Pfizer, Synflorix, pneumococcal vaccine, pneumonia, prevenar 13, vaccines
International medical aid charity Médecins Sans Frontières/Doctors Without Borders (MSF) is taking action against GlaxoSmithKline and Pfizer, calling on the …
LEO Pharma buys dermatology portfolio from Astellas
November 12, 2015Sales and Marketing Astellas, LEO Pharma, acquisitions, dermatology, mergers
LEO Pharma, the speciality dermatology firm, is looking to expand its presence in the therapy area by buying Astellas’ portfolio …
Astellas to acquire Ocata Therapeutics in $379m buyout
November 11, 2015Research and Development, Sales and Marketing Astellas, Ocata, Stem cells, cell therapy, ophthalmology
Astellas Pharma has agreed to buy Ocata, a firm specialising in cloning and embryonic stem cell therapies, for $379 million. …
FDA approves Roche skin cancer combination
November 11, 2015Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib
The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …
UK ‘lacks the skills’ for future drug development, ABPI warns
November 11, 2015Business Services, Research and Development ABPI, Jobs, careers, recruitment, skills gap
A shortage of skilled professionals threatens to undermine research and development of new medicines in the UK and prevent growth …
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
Lilly/Incyte RA drug bests Humira in Phase III trial
November 10, 2015Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis
Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …
ABPI welcomes science budget inquiry findings
November 10, 2015Manufacturing and Production, Research and Development ABPI, Comprehensive Spending Review
The UK pharma trade body, the ABPI, has welcomed the findings of the Science and Technology Committee’s inquiry into the …
All Party Parliamentary Group for Life Sciences CSR letter to the Chancellor, Business Secretary and Science Ministers
November 10, 2015Manufacturing and Production, Research and Development Chancellor, Comprehensive Spending Review, George Osborne
Dear Mr Osborne,Ahead of the forthcoming Comprehensive Spending Review I am sure you will have received many letters from across …
Janssen buys licence to diabetes and obesity drugs from Hanmi
November 10, 2015Manufacturing and Production, Research and Development Janssen, diabetes, hanmi
Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity. …
FDA warnings create woe for Indian drugmakers
November 10, 2015Manufacturing and Production CGMP, Dr Reddy's, Dr. Reddy's, FDA, India, Sun Pharma, manufacturing, production
Recent enforcement action has taken its toll on the fortunes of several Indian pharmaceutical manufacturers, with Sun Pharmaceuticals and Dr. …
Sanofi Pasteur ‘actively exploring’ universal flu vaccine
November 10, 2015Manufacturing and Production, Research and Development SEEK, Sanofi Pasteur, influenza, universal flu vaccine
Sanofi Pasteur is developing a universal, cross-reactive antigen against seasonal and pandemic influenza, the company has revealed.The French firm presented its …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
Health minister criticised for blocking Off-Patent Drugs Bill debate
November 9, 2015Research and Development, Sales and Marketing Alistair Burt, Breast Cancer Now, MS Society, Off-Patent Drugs Bill
A Parliamentary Bill backing the wider use of off-patent drugs has been kicked into the long grass after the Government …
EMA concludes HPV vaccines do not cause CRPS or POTS
November 9, 2015Sales and Marketing EMA, HPV, HPV vaccine, PRAC, complex regional pain syndrome, drug safety, postural orthostatic tachycardia syndrome
The European Medicines Agency says there is no evidence from a detailed scientific review of reports linking complex regional pain …
Medicines Patent Pool to include hep C and TB drugs
November 9, 2015Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis
The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …
Governments and industry ‘combining to stall drug development’
November 9, 2015Research and Development, Sales and Marketing BMJ, R&D, drug development
Both government and industry practices are responsible for the innovation deficit in the pharmaceutical sector, meaning that “the majority of …
Pfizer to double patient assistance allowance in the US
November 9, 2015Sales and Marketing Drug pricing, Pfizer
Pfizer says it will double the allowable income level for its RxPathways patient assistance program in the US with immediate …
GSK asthma drug Nucala gets FDA approval
November 6, 2015GSK, Nucala, asthma, eosinophils, mepolizumab
GlaxoSmithKline has received approval from the FDA for Nucala as an add-on maintenance treatment of patients with severe asthma aged …
Boehringer announces board changes, chairman’s retirement
November 6, 2015Medical Communications, Sales and Marketing
Boehringer Ingelheim has announced that Professor Andreas Barner will retire as chairman of the Board of Managing Directors on 30 …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
